Pfizer's COVID-19 Impact: Lower Profit Projections
Update: 2025-12-16
Description
Pfizers financial outlook for 2026 disappoints, with lower COVID product sales projected, leading to a dip in stock price. The company anticipates adjusted profits of $2.80 to $3.00 per share, below analysts estimates of $3.05. Revenue projections also fall short, with a range of $59.5B to $62.5B, compared to the analyst consensus of $61.59B. This shift reflects the pharmaceutical industrys adjustment as demand for pandemic-related solutions wanes.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
